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Background
Hemophilia B, an X-linked disorder, is ideally suited for gene therapy. We investigated 
the use of a new gene therapy in patients with the disorder.
Methods
We infused a single dose of a serotype-8–pseudotyped, self-complementary adeno-
virus-associated virus (AAV) vector expressing a codon-optimized human factor IX 
(FIX) transgene (scAAV2/8-LP1-hFIXco) in a peripheral vein in six patients with severe 
hemophilia B (FIX activity, <1% of normal values). Study participants were enrolled se-
quentially in one of three cohorts (given a high, intermediate, or low dose of vector), 
with two participants in each group. Vector was administered without immunosuppres-
sive therapy, and participants were followed for 6 to 16 months.
Results
AAV-mediated expression of FIX at 2 to 11% of normal levels was observed in all par-
ticipants. Four of the six discontinued FIX prophylaxis and remained free of sponta-
neous hemorrhage; in the other two, the interval between prophylactic injections was 
increased. Of the two participants who received the high dose of vector, one had a tran-
sient, asymptomatic elevation of serum aminotransferase levels, which was associated 
with the detection of AAV8-capsid–specific T cells in the peripheral blood; the other 
had a slight increase in liver-enzyme levels, the cause of which was less clear. Each of 
these two participants received a short course of glucocorticoid therapy, which rap-
idly normalized aminotransferase levels and maintained FIX levels in the range of 
3 to 11% of normal values.
Conclusions
Peripheral-vein infusion of scAAV2/8-LP1-hFIXco resulted in FIX transgene expres-
sion at levels sufficient to improve the bleeding phenotype, with few side effects. 
Although immune-mediated clearance of AAV-transduced hepatocytes remains a con-
cern, this process may be controlled with a short course of glucocorticoids without 
loss of transgene expression. (Funded by the Medical Research Council and others; 
ClinicalTrials.gov number, NCT00979238.)
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Hemophilia B is an X-linked bleed-ing disorder that results from a defect in the gene encoding coagulation factor IX 
(FIX), a serine protease that is critical for blood 
clotting. Persons with severe hemophilia B have 
functional FIX levels that are less than 1% of nor-
mal values and have frequent bleeding episodes, 
which are associated with crippling arthropathy 
and early death.1,2 Current treatment involves fre-
quent intravenous injections of FIX protein con-
centrate (i.e., two to three times a week). However, 
this treatment is prophylactic rather than curative, 
is extremely expensive, and is associated with in-
hibitor formation. Somatic gene therapy for he-
mophilia B offers the potential for a cure through 
continuous endogenous production of FIX after a 
single administration of vector, especially since a 
small rise in circulating FIX to at least 1% of nor-
mal levels can substantially ameliorate the bleed-
ing phenotype.
At present, gene transfer mediated by an ade-
novirus-associated virus (AAV) vector shows the 
greatest promise for long-term correction of he-
mophilia B in the preclinical setting.3-7 However, 
a combined phase 1 and 2 study that involved se-
rotype 2–based AAV vectors (AAV2) showed only 
transient expression of FIX and suggested that 
stable expression of therapeutic levels of FIX may 
be limited by a capsid-specific cytotoxic T-cell 
response against the transduced hepatocytes.8,9
We have tested an approach to treating patients 
with severe hemophilia B that is distinct from the 
approaches used in previous clinical trials of AAV-
mediated gene transfer in three important re-
spects. First, we developed a codon-optimized FIX 
(FIXco) expression cassette that is packaged as 
complementary dimers within a single virion. 
These self-complementary AAV (scAAV) vectors 
mediate transgene expression at substantially 
higher levels than do single-stranded AAV vec-
tors.6,10 Second, to circumvent the possibility of 
humoral immunity to AAV, we pseudotyped these 
vectors with a capsid of serotype 8 (AAV8), which 
has a lower seroprevalence in humans than does 
AAV2.11,12 Finally, since AAV8 has a strong tro-
pism for the liver, we were able to administer the 
vector in the peripheral vein — a simple, nonin-
vasive approach that is safe for patients with a 
bleeding diathesis. On the basis of our preclinical 
safety and efficacy data, we conducted a com-
bined phase 1 and 2 clinical trial of scAAV2/8-




Patients who met the entry criteria and did not have 
neutralizing antibodies to AAV8, as determined by 
an in vivo transduction-inhibition assay (see Table 
1 and the Methods section in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org), were enrolled after providing 
written informed consent. Participants 1 through 
5 were recruited in 2010 and Participant 6 was 
recruited early in 2011. All were admitted to the 
Royal Free Hospital for vector administration and 
subsequent observation overnight. Participants 
were enrolled sequentially into one of three co-
horts according to dose level: low (2×1011 vector 
genomes [vg] per kilogram of body weight), in-
termediate (6×1011 vg per kilogram), and high 
(2×1012 vg per kilogram).
The study was sponsored by St. Jude Children’s 
Research Hospital and was conducted indepen-
dently by the authors in accordance with the 
protocol, which is available at NEJM.org, and 
with the provisions of the Good Clinical Practice 
guidelines.
Vector Production and Formulation
The viral vector, scAAV2/8-LP1-hFIXco, has been 
described previously.6,10 It was manufactured and 
formulated in phosphate-buffered saline (PBS) sup-
plemented with 0.25% human serum albumin by 
the Children’s GMP, in Memphis, Tennessee, in ac-
cordance with Good Manufacturing Practice and 
regulatory requirements.13 The vector titer initially 
reported was determined by means of a validated, 
quantitative real-time polymerase-chain-reaction 
(qPCR) assay.14 Subsequent studies have shown that 
with the qPCR assay, the presence of the covalently 
closed hairpin at one end of the scAAV-vector ge-
nome results in an underestimate of the titer by a 
factor of almost 10; therefore, the doses reported 
here are based on titers determined by a method 
that circumvents this issue and results in more ac-
curate and reliable vector-genome titration of the 
scAAV vector (see Methods in the Supplementary 
Appendix).15 Preparation and infusion of the vector 
are described in the protocol.
Safety and Efficacy Assessments
Assessments performed after vector infusion in-
cluded vital signs, as well as plasma FIX activity, 
anti-capsid and anti-FIX antibody levels, vector 
shedding, and cellular immune response.8-10,16 Ef-
The New England Journal of Medicine 
Downloaded from nejm.org on December 11, 2011. For personal use only. No other uses without permission. 
 From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Vector-Mediated Gene Tr ansfer in Hemophilia B
10.1056/nejmoa1108046  nejm.org 3
ficacy was defined as the persistence of biologi-
cally active FIX at 3% or more of normal levels.
R esult s
Characteristics of the Study Participants
Six men with severe hemophilia B (FIX activity, 
<1% of normal values) were enrolled under a pro-
tocol approved by the relevant ethics boards and 
regulatory agencies, after providing written in-
formed consent. All except one participant re-
ceived regular prophylaxis with FIX concentrates 
(two or three times per week) before gene transfer 
(Table 1). Participant 4 was receiving targeted pro-
phylaxis (about once weekly), which was tailored 
to his sports activities and the associated risk of 
traumatic injury. Participant 2 had a null mutation 
in the FIX gene, and Participant 6 had a promoter 
mutation; consequently, neither had FIX protein 
expression. The other four participants had mis-
sense mutations, which resulted in normal plasma 
levels of FIX antigen but less than 1% clotting ac-
tivity. All participants had modest levels (>5 rela-
tive units) of anti-AAV2 IgG antibodies before gene 
transfer.
Safety and Efficacy of Peripheral-Vein 
Infusion of Vector
No immediate changes in vital signs were noted 
during or after vector infusion in any participant, 
despite the persistence of the vector in bodily flu-
ids (including plasma) for up to 15 days after gene 
transfer (Fig. 1 in the Supplementary Appendix). 
There were no clinically significant changes in se-
rum chemical values (including liver enzyme lev-
els) in any participant for the first 6 weeks after 
vector infusion (Fig. 2 in the Supplementary Ap-
pendix). Three adverse events were reported: ane-
mia developed in Participants 1 and 2 at 5 and 7 
weeks, respectively, after gene transfer, and Par-
ticipant 3 had a transient period of bradycardia at 
16 weeks after gene transfer, when he was being 
prepared for surgery on his left knee (see the Sup-
plementary Appendix for details).
Low-Dose Group
In Participant 1, after the initial clearance of exog-
enously administered FIX protein, plasma FIX ac-
tivity stabilized at 2% of normal levels on day 14 
after the infusion of 2×1011 vg of scAAV2/8-LP1-
hFIXco per kilogram. FIX activity remained rela-
tively stable at this level for more than 16 months 
after gene transfer, despite the discontinuation 
of twice-weekly FIX prophylaxis (Fig. 1A). This 
level was substantially higher than his baseline 
FIX activity level (<1% of normal levels) and is con-
sistent with endogenous synthesis of FIX. He had 
no spontaneous hemorrhages during this period, 
but FIX prophylaxis was required on five occasions 
to provide protection in the event of accidental 
injuries and during elective surgery.
In Participant 2, the plasma FIX level was 1% of 
normal levels 18 days after gene transfer, which 
was 3 weeks after his last injection of FIX con-
centrate. Although this level was consistent with 
endogenous synthesis of transgenic FIX, he con-
tinued to have spontaneous hemorrhages and 
resumed regular FIX prophylaxis. Over time, he 
gradually increased the interval between prophy-
lactic FIX injections to 2 weeks, with no sponta-
neous hemorrhages. At 23 weeks after gene trans-
fer and 3 weeks after the last FIX concentrate 
injection, his plasma FIX level was 2% of normal 
values, which suggested ongoing endogenous FIX 
synthesis (Fig. 1B).
Intermediate-Dose Group
In Participant 3, the level of FIX activity in plasma 
consistently drifted downward to below 1% of 
normal values in the absence of FIX concentrate 
during the first 5 weeks after the infusion of 
6×1011 vg of scAAV2/8-LP1-hFIXco per kilogram. 
This change raised the possibility that the trans-
duction of hepatocytes was blocked because the 
level of anti-AAV8 antibody before gene transfer 
was higher in this participant than in the other 
participants (Table 1). However, over time, Partici-
pant 3 extended the period between prophylactic 
FIX injections to 2 weeks. Between weeks 20 and 
33, he did not receive FIX prophylaxis and remained 
free of spontaneous bleeding. During this period, 
his plasma FIX level was between 1 and 3% of 
normal values, which is consistent with endoge-
nous synthesis of transgenic protein (Fig. 1C).
Plasma FIX levels in Participant 4 increased 
from a baseline value of less than 1% of normal 
values to a peak of 4% 4 weeks after gene trans-
fer. FIX expression remained at this level for almost 
3 months before declining to 2 to 3% of normal 
values (Fig. 1D). The reason for this decline is un-
clear, since the results of liver-function tests re-
mained in the normal range, and assays for neu-
tralizing anti-FIX antibodies were consistently 
negative. Despite this drop in FIX activity, he had 
no bleeding episodes, even though he engaged in 
physical activities that had previously provoked 
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such episodes (e.g., playing soccer and cricket 
without having received targeted prophylaxis). Ap-
proximately 9 weeks after gene transfer, however, 
he did receive a bolus of FIX concentrate to prevent 
severe bleeding after a fall.
High-Dose Group
Fourteen days after peripheral-vein infusion of 
2×1012 vg of scAAV2/8-LP1-hFIXco per kilogram 
(17 days after the last infusion of FIX concentrate), 











































































































































Figure 1. Factor IX (FIX) Activity after Peripheral-Vein Infusion of the Adenovirus-Associated Virus (AAV) Vector 
in the Six Study Participants.
A one-stage clotting assay was used to determine FIX coagulation activity at prespecified time points (arrows) after 
the administration of the AAV vector (scAAV2/8-LP1-hFIXco). Panels A and B show FIX levels in Participants 1 and 2, 
respectively, who received the low dose of vector (2×1011 vector genomes [vg] per kilogram of body weight). Panels C 
and D show FIX levels in Participants 3 and 4, respectively, who received the intermediate dose of vector (6×1011 vg 
per kilogram). Panels E and F show both FIX levels and alanine aminotransferase (ALT) levels in Participants 5 and 6, 
respectively, who received the high dose of vector (2×1012 vg per kilogram). The duration of treatment with pred-
nisolone (Pred), which was initiated at a dose of 60 mg per day and then gradually tapered, is also shown.
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normal values, and this level was maintained un-
til week 7 without the administration of concen-
trate. On day 49 after the vector infusion, aspartate 
aminotransferase and alanine aminotransferase 
levels were elevated, reaching peaks of 143 and 
202 IU per liter, respectively, at 58 days (upper limit 
of the normal range, 37 and 41 IU per liter, respec-
tively). He was asymptomatic, with normal biliru-
bin levels and prothrombin time, but the plasma 
FIX level dropped to 3% of normal values (Fig. 1E). 
After ruling out possible causes of this reduction, 
such as autoimmune responses, toxic factors (al-
cohol, drugs, or toxins), or infectious viral causes 
(hepatitis A, B, C, or E virus, herpes simplex virus, 
Epstein–Barr virus, cytomegalovirus, human im-
munodeficiency virus, or human T-lymphotrophic 
virus type I or II), we considered an immunologic 
response to scAAV2/8-LP1-hFIX as a potential ex-
planation for the liver injury. This was reported as 
a grade 3 adverse event related to the study agent. 
Treatment with prednisolone was begun on day 
58 at a dose of 60 mg per day, with subsequent ta-
pering of the dose, rapidly reducing aminotransfer-
ase levels. Nine weeks after glucocorticoid therapy 
was discontinued, transgene expression persisted 
at the 3% level, and the results of liver-function 
tests remained in the normal range. The patient 
was free of spontaneous hemorrhage for more than 
6 months after the gene transfer but required 
three boluses of FIX concentrate to prevent bleed-
ing due to traumatic injuries sustained during a 
recent geologic field trip.
In Participant 6, plasma FIX expression re-
mained between 8 and 12% of normal levels dur-
ing an 8-week period after vector administration. 
He was able to stop FIX prophylaxis even while he 
was training for a marathon. Clinical and labora-
tory measures remained within the normal range 
until week 9 (day 62 after gene transfer), when 
aspartate aminotransferase and alanine amino-
transferase values roughly doubled, as compared 
with baseline levels (with both reaching 36 IU per 
liter). This change followed a weekend of intensive 
physical activity, which included participation in a 
half-marathon, and was associated with a rise in 
the level of lactate dehydrogenase (to 523 IU per 
liter; normal range, 240 to 480). When FIX activity 
declined to 5% of normal levels, Participant 6 also 
began a short (4-week) course of prednisolone for 
suspected immune-mediated hepatocyte clearance 
after other possible causes had been ruled out. 
Aminotransferase levels subsequently returned to 
baseline values, and FIX expression remained at a 
level that was between 8 and 12% of normal val-
ues (Fig. 1F). However, even at their peak, liver 
enzyme levels in Participant 6 remained below 
the upper limit of the normal range and therefore 
did not meet the criteria for an adverse event.
Immune Responses to Vector and Transgene
Neutralizing antibodies to FIX were not detected at 
any time point in any participant. The kinetic char-
acteristics of the humoral immune response to the 
AAV8 capsid were similar in all six participants and 
were consistent with a primary immune response 
to AAV8 (Fig. 2 and Table 1, and Results in the 
Supplementary Appendix).
T-cell–mediated immune responses to the FIX 
transgene or putative products of translation from 
alternative open reading frames in the codon-opti-
mized FIX complementary DNA17 were not detect-
able in any of the participants (data not shown), as 
determined with the use of an interferon-γ en-
zyme-linked immunosorbent spot (ELISPOT) as-
say. The same assay showed that participants in 
the low-dose cohort did not have significant AAV8-
capsid–specific T-cell responses after gene trans-
fer. At the intermediate-dose level, a significant 
increase in the frequency of AAV8-capsid–specific 
T cells was observed. In particular, Participant 3 
had T-cell reactivity to the AAV capsid until week 
33 after the gene transfer (Fig. 3), and Participant 




























































Figure 2. Humoral Immune Response in Participant 1.
The profile of the humoral immune response in Participant 1 is representa-
tive of the responses seen in the other participants. Plasma samples ob-
tained after peripheral-vein infusion of the scAAV2/8-LP1-hFIXco vector 
were analyzed with the use of an enzyme-linked immunosorbent assay for 
the presence of AAV8-specific IgM antibodies, total IgG antibodies, and 
IgG isotypes. Data for the IgG1 isotype are shown. IgG2 and IgG4 levels 
did not increase above baseline (data not shown).
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at week 2 (about 1700 spot-forming units [SFU] 
per 1 million peripheral-blood mononuclear cells 
[PBMCs]). At the highest dose level, an increase in 
circulating AAV8-capsid–specific T cells was ob-
served in Participant 5 starting at week 5 after 
transduction and reaching a peak of more than 
500 SFU per 1 million PBMCs by week 8, which 
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Figure 3. Cellular Immune Response in the Six Study Participants.
Results of the interferon-γ enzyme-linked immunosorbent spot assay for capsid-specific T-cell responses are shown as the maximum 
number of spot-forming units (SFU) per 1 million peripheral-blood mononuclear cells (PBMCs) in response to AAV8-capsid peptide 
pools. The horizontal lines in each panel represent the threshold for positivity, defined as three times the T-cell response for the nega-
tive control (medium only) and as at least 50 SFU per 1 million PBMCs. Liver-enzyme levels were elevated in Participant 5 at weeks 8 
and 9 and in Participant 6 at week 9. In Participant 6, poor cell recovery and viability were noted at weeks 4 through 8.
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levels. In this participant, broad reactivity was 
observed across the six capsid peptide pools as-
sessed (Fig. 3 in the Supplementary Appendix). 
By week 10, capsid-specific T cells were once again 
undetectable. No T-cell reactivity to the AAV cap-
sid was detectable in PBMCs from Participant 6 
until week 8 after the gene transfer, although this 
may have been due in part to reduced cell recovery 
and viability. At weeks 9 and 10, capsid-specific 
T cells became detectable, with levels of up to ap-
proximately 200 SFU per 1 million PBMCs, a find-
ing that was concomitant with the minor increase 
in liver enzyme levels.
Discussion
The development and widespread use of clotting 
factor concentrates for the treatment of hemophil-
ia in the early 1970s dramatically improved the life 
expectancy for patients with the disease. Subse-
quent development of recombinant clotting factor 
concentrates has improved their safety profile, but 
there remains a strong interest in treatment strate-
gies that would eliminate the need for long-term 
intravenous infusions and that would be available 
to the hemophilia population throughout the 
world. This study documents a critical step toward 
that goal and shows that sustained therapeutic 
expression of a transferred factor IX gene can be 
achieved in humans. The increase in FIX levels in 
our study participants was roughly dose-dependent, 
with the high dose of the vector scAAV2/8-LP1-
hFIX (2×1012 vg per kilogram) mediating peak 
expression at 8 to 12% of normal levels. After 
peripheral-vein administration of scAAV2/8-LP1-
hFIXco, four of the six participants were able to 
stop using prophylaxis with FIX concentrate with-
out having spontaneous hemorrhage, even when 
they undertook activities that had provoked bleed-
ing in the past. For the other two participants, the 
interval between prophylactic FIX concentrate injec-
tions was extended, but prophylaxis was not com-
pletely discontinued. These two participants had 
severe preexisting hemophilic arthropathy. Maxi-
mal protection from bleeding in this subgroup may 
require higher endogenous expression of FIX.18
None of the participants had an immunologic 
response to the FIX transgene product. As reported 
in previous studies, the kinetics and magnitude 
of capsid-specific T-cell responses in PBMCs were 
highly variable in our study, with the highest num-
ber of capsid-specific T cells detected in Partici-
pant 4 at 2 weeks after gene transfer.8,19,20 There 
was no evidence of hepatocellular injury in this 
participant, suggesting that the T-cell repertoire 
in peripheral blood may be distinct from that in 
the liver or that levels of AAV8-capsid–antigen pre-
sentation on major-histocompatibility-complex 
class I hepatocytes were insufficient to drive the 
immune-mediated clearance of transduced cells. 
A scenario consistent with AAV8-capsid–specific 
T-cell–mediated destruction of transduced hepato-
cytes was observed 7 weeks after gene transfer in 
Participant 5. It is less certain whether the small 
increase in liver enzyme levels 9 weeks after gene 
transfer in Participant 6 was due to immune-
mediated destruction of transduced hepatocytes. 
This increase occurred after a period of intense 
physical exertion, which is known to increase ami-
notransferase and lactate dehydrogenase levels.21,22 
In both Participant 5 and Participant 6, the initia-
tion of prednisolone therapy was followed by a 
return of the aminotransferase levels to baseline 
values and the disappearance of capsid-specific 
T cells from peripheral blood. Arguably, this could 
have happened without glucocorticoid treatment, 
since at 7 weeks after gene transfer, many of the 
transduced hepatocytes will have cleared the pro-
voking AAV8 capsid peptide through natural pro-
teolytic degradation and would therefore escape 
elimination by effector T cells.
The different outcomes of gene transfer in the 
participants in this study and in the previous trial 
of AAV2 hemophilia B gene therapy8 suggest that 
in addition to AAV vector dose, other factors such 
as individual variations in antigen processing and 
presentation, as well as exposure to wild-type AAV, 
seem to influence the type and magnitude of the 
immunological response to AAV-vector particles.23 
It is very important to identify these immuno-
modifying factors, as well as to determine the 
frequency of clinically significant elevations in 
aminotransferase levels after gene transfer. How-
ever, this will require a larger number of partici-
pants treated at the high-dose level. Currently, we 
do not think that routine use of a course of pro-
phylactic glucocorticoids is indicated, since the 
incidence and timing of immune-mediated ele-
vations in aminotransferase levels are uncertain, 
whereas early intervention, when needed, appears 
to be effective at curbing the immune response to 
transduced hepatocytes.
In summary, we have found that a single pe-
ripheral-vein infusion of our scAAV2/8-LP1-hFIXco 
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vector consistently leads to long-term expression of 
the FIX transgene at therapeutic levels, without 
acute or long-lasting toxicity in patients with severe 
hemophilia B. Immune-mediated, AAV-capsid–
induced elevations in aminotransferase levels re-
main a concern, but our data suggest that this 
process may be controlled by a short course of 
glucocorticoids, without loss of transgene expres-
sion. Follow-up of larger numbers of patients for 
longer periods of time is necessary to fully define 
the benefits and risks and to optimize dosing. 
However, this gene-therapy approach, even with 
the associated risk of transient hepatic dysfunc-
tion, has the potential to convert the severe bleed-
ing phenotype into a mild form of the disease or 
to reverse it entirely.
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